A conflict-of-interest statement is worth reading aloud and is worth very little as a predictor. Design quality is what to spend the session on.
I have kept the units in throughout, for the obvious reason.
A conflict-of-interest statement is worth reading aloud and is worth very little as a predictor. Design quality is what to spend the session on.
I have kept the units in throughout, for the obvious reason.
Post #5 and I disagree about the size of the effect, not about the direction.
Reading order that works for these sessions: registry entry, methods, baseline table, primary result, then abstract last. Reading the abstract first anchors everything that follows.
Quietly grateful for the plain phrasing. Not every thread gets that.
My understanding of STEP 4 is a few years old and may have been superseded. If it has been, I would genuinely like to know rather than keep repeating it.
The summary that goes to the digest should say what the paper establishes, what it does not, and one thing the group could not settle. Three paragraphs, no more.
The variance between people here is larger than the effect being discussed.
Two sentences on STEP 4 and then I will stop, because the rest is speculation and the thread is better without mine.
What is documented is narrow. What is inferred from it is broad. The gap between them is where every argument here lives.
Read the full topic (63 posts)
| Topic | Participants | Replies | Views | Activity |
|---|---|---|---|---|
|
[2026 update] Journal club: FLOW and the renal composite, component by component
Journal club: FLOW and the renal composite, component by component Writing it up because I had to work it out twice and would rather nobody else did. A question about what the numbers mean rather than what…
|
2 | 21k | 9d | |
|
Second pass at: Journal club: LEADER as the historical anchor
Posting this under the heading it deserves: Second pass at: Journal club: LEADER as the historical anchor Everything below is what sits behind that. Two things I would like separated before anyone answers on…
|
+75 | 81 | 2k | 2y |
|
[2026 update] Journal club: is percentage weight change the right endpoint?
Journal club: is percentage weight change the right endpoint? — that is the question, and I have not found it answered plainly anywhere I have looked. A question about what the numbers mean rather than what…
|
+105 | 118 | 18k | 11mo |
|
Journal club: SURMOUNT-OSA and a hard endpoint in a soft field
Posting this under the heading it deserves: Journal club: SURMOUNT-OSA and a hard endpoint in a soft field Everything below is what sits behind that. Collecting what is known about SURMOUNT-OSA in one place,…
|
+47 | 51 | 617 | 16mo |
|
Journal club: SUSTAIN 6 and its retinopathy signal
On the subject in the title: Journal club: SUSTAIN 6 and its retinopathy signal Working notes rather than a conclusion. Reading SUSTAIN 6 ( N Engl J Med , 2016) for the population rather than the effect,…
|
+110 | 122 | 46k | 1d |
| Topic | Participants | Replies | Views | Activity |
|---|---|---|---|---|
|
A well-designed study with a badly written abstract — does this still hold?
A well-designed study with a badly written abstract — does this still hold? I have a specific reason for asking rather than idle curiosity, and the context is below. Asking about well-designed study on behalf…
|
2 | 28k | 20mo | |
|
A 40-week log with the measurement method stated — does this still hold?
A 40-week log with the measurement method stated — does this still hold? I have a specific reason for asking rather than idle curiosity, and the context is below. Posting a small dataset on 40-week log. It is…
|
+1 | 5 | 14k | 2mo |
|
SURPASS-2 and the comparator dose question that will not go away
SURPASS-2 and the comparator dose question that will not go away — setting out what I have, and where I think it stops being reliable. A methods question rather than a substantive one, about SURPASS-2.…
|
+101 | 111 | 1.5k | 18mo |
|
Second pass at: Triple agonism: additive, synergistic, or neither?
Second pass at: Triple agonism: additive, synergistic, or neither? — that is the question, and I have not found it answered plainly anywhere I have looked. Posting a small dataset on Triple agonism. It is…
|
+114 | 120 | 1.4k | 10mo |
|
Retatrutide dose escalation in the published trials
Posting this under the heading it deserves: Retatrutide dose escalation in the published trials Everything below is what sits behind that. An honest uncertainty about retatrutide dose escalation rather than a…
|
+149 | 159 | 30k | 15mo |